High-power (80 W) potassium titanyl phosphate laser prostatectomy in 128 high-risk patients.

To evaluate the safety and merits of 80 W potassium titanyl phosphate (KTP) laser prostatectomy in men with high cardiovascular or pulmonary risk, receiving oral anticoagulant medication, or with bleeding disorders.
A prospective clinical trial was performed in 128 high-risk men with benign prostatic hyperplasia who underwent photoselective vaporisation of the prostate (PVP). The operation time, postoperative serum sodium and packed cell volume were recorded. The International Prostate Symptom Score (IPSS), maximal flow rate (Q(max)) and post-void residual urine volume (PVR) were measured at every follow-up visit.
In all patients, KTP laser prostatectomy was performed successfully. The mean (SD) operation time was 51.6 (22.8) min. No blood transfusions were required. No major complications occurred during surgery, and there was no mortality. The mean (SD) catheterisation time was 2.8 (1.6) days. IPSS decreased from 19.2 (6.1) before surgery to 11.5 (8.2), 7.8 (6.4), 6.7 (5.3) and 6.1 (4.6), respectively, at 1, 3, 6 and 12 months after. Q(max) increased from 7.0 (2.8) ml/s to 14.5 (9.3), 20.2 (11.5), 21.3 (8.6) and 24.8 (8.0) ml/s, respectively. PVR decreased from 168 (89) ml to 35 (29), 30 (26), 27 (21) and 23 (34) ml, respectively.
80 W KTP laser prostatectomy is a virtually bloodless, safe and effective procedure for men with high cardiovascular or pulmonary risk or bleeding disorders or taking oral anticoagulant medication.
AuthorsJ Yuan, H Wang, G Wu, H Liu, Y Zhang, L Yang
JournalPostgraduate medical journal (Postgrad Med J) Vol. 84 Issue 987 Pg. 46-9 (Jan 2008) ISSN: 1469-0756 [Electronic] England
PMID18230751 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Anticoagulants
  • Phosphates
  • potassium titanylphosphate
  • Titanium
  • Aged
  • Aged, 80 and over
  • Anticoagulants (administration & dosage)
  • Blood Loss, Surgical (prevention & control)
  • Cardiovascular Diseases (complications, drug therapy)
  • Follow-Up Studies
  • Humans
  • Laser Therapy (adverse effects)
  • Male
  • Middle Aged
  • Phosphates
  • Prospective Studies
  • Prostatic Hyperplasia (complications, surgery)
  • Risk Factors
  • Titanium
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: